购物车
- 全部删除
- 您的购物车当前为空
Trastuzumab rezetecan (SHR-A1811) 是一种针对HER2阳性的抗体偶联药物 (ADC)。该药物由人源化抗HER2抗体、可裂解的连接肽MC-Gly-Gly-Phe-Gly以及作为有效载荷的拓扑异构酶I抑制剂Rezetecán构成。Trastuzumab rezetecan主要用于HER2阳性乳腺癌的研究。
Trastuzumab rezetecan (SHR-A1811) 是一种针对HER2阳性的抗体偶联药物 (ADC)。该药物由人源化抗HER2抗体、可裂解的连接肽MC-Gly-Gly-Phe-Gly以及作为有效载荷的拓扑异构酶I抑制剂Rezetecán构成。Trastuzumab rezetecan主要用于HER2阳性乳腺癌的研究。
产品描述 | Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer. |
别名 | SHR-A1811 |
CAS No. | 2924909-11-3 |
存储 | store at -20°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容